RayThera

RayThera is a private, preclinical-stage biotechnology company focused on small molecule drug discovery for immunological diseases. The company is led by a highly experienced founding team with a proven track record of building and exiting biotech ventures, including XinThera (acquired by Gilead) and FronThera. Backed by notable life science investors like Foresite Capital and OrbiMed, RayThera employs an efficient, expertise-driven model to advance its pipeline of anti-inflammatory candidates from lead generation through preclinical development.

Expertise-driven small molecule drug discovery platform leveraging decades of experience in structure-based design and biology for immunology targets, emphasizing a nimble, integrated operational model.

RayThera operates in the highly competitive immunology space, competing against large pharmaceutical companies with extensive resources and numerous biotechs. Its differentiation lies in its founders' exceptional serial success record and efficient, expertise-driven operational model for early discovery.